Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Current Assets
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Current Assets Peer Comparison
Competitive Other Current Assets Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Other Current Assets
ÂĄ388.9m
|
CAGR 3-Years
34%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Assets
ÂĄ129.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Current Assets
ÂĄ365.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Assets
ÂĄ1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
21%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Assets
ÂĄ458.8m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
0%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Current Assets
ÂĄ70.3m
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Assets?
Other Current Assets
388.9m
CNY
Based on the financial report for Mar 31, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Assets amounts to 388.9m CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
40%
Over the last year, the Other Current Assets growth was 288%. The average annual Other Current Assets growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 34% over the past three years , 40% over the past five years .